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RESE ARCH ARTICLE

Propofol inhibits the voltage-gated sodium channel
NaChBac at multiple sites
Yali Wang1, Elaine Yang2, Marta M. Wells1,3, Vasyl Bondarenko1, Kellie Woll4, Vincenzo Carnevale5, Daniele Granata5, Michael L. Klein5,
Roderic G. Eckenhoff4, William P. Dailey6, Manuel Covarrubias2, Pei Tang1,3,7, and Yan Xu1,7,8,9

Voltage-gated sodium (NaV) channels are important targets of general anesthetics, including the intravenous anesthetic
propofol. Electrophysiology studies on the prokaryotic NaV channel NaChBac have demonstrated that propofol promotes
channel activation and accelerates activation-coupled inactivation, but the molecular mechanisms of these effects are
unclear. Here, guided by computational docking and molecular dynamics simulations, we predict several propofol-binding
sites in NaChBac. We then strategically place small fluorinated probes at these putative binding sites and experimentally
quantify the interaction strengths with a fluorinated propofol analogue, 4-fluoropropofol. In vitro and in vivo measurements
show that 4-fluoropropofol and propofol have similar effects on NaChBac function and nearly identical anesthetizing effects
on tadpole mobility. Using quantitative analysis by 19F-NMR saturation transfer difference spectroscopy, we reveal strong
intermolecular cross-relaxation rate constants between 4-fluoropropofol and four different regions of NaChBac, including
the activation gate and selectivity filter in the pore, the voltage sensing domain, and the S4–S5 linker. Unlike volatile
anesthetics, 4-fluoropropofol does not bind to the extracellular interface of the pore domain. Collectively, our results show
that propofol inhibits NaChBac at multiple sites, likely with distinct modes of action. This study provides a molecular basis
for understanding the net inhibitory action of propofol on NaV channels.

Introduction

Excitable cells such as neurons and myocardia communicate
with each other by alternating electrical and chemical signals.
The electric impulses travel along the cell surface by means of
depolarization and repolarization involving the flow of Na+ and
K+ ions in opposite directions across the cell membrane. The voltage-gated sodium (NaV) channels, which typically conduct the
Na+ current inward, are responsible for controlling the initiation
and propagation of action potentials. NaV channels are involved
in a variety of physiological processes, including skeletal muscle
contraction, heart rhythm, and neurotransmission. Accordingly,
drugs that affect NaV channel function include anticonvulsants,
antiarrhythmics, and antiepileptics, as well as local anesthetics
(Amarouch and Abriel, 2015; Habib et al., 2015; Lin and Baines,
2015; Jeevaratnam et al., 2016).
Unlike local anesthetics, it has been widely believed that general anesthetics primarily exert their action by targeting postsynaptic ligand-gated ion channels (Eckenhoff and Johansson,

1997; Tang and Xu, 2002; Liu et al., 2009; Chen et al., 2010; Pan et
al., 2012; Mowrey et al., 2013; Tillman et al., 2013; Bondarenko et
al., 2014). However, recent experimental evidence suggests that
NaV channels also play a critical role in the disruption of synaptic
transmission by general anesthetics. Several functional studies
with heterologously expressed eukaryotic NaV channels (OuYang
and Hemmings, 2007; Purtell et al., 2015) and their bacterial
counterparts (Hemmings et al., 2005; Barber et al., 2014; Kinde
et al., 2016; Sand et al., 2017) have demonstrated that clinically
relevant concentrations of general anesthetics can inhibit the
function of NaV channels. Although local anesthetics are known
to block the NaV channel pore and stabilize the inactivated state
(Goldschen-Ohm and Chanda, 2014), the modes of action of general anesthetics on NaV channels remain elusive.
General anesthetics bind to their protein targets, including
NaV channels, with relatively low affinity (high micromolar to
low millimolar) and high exchange rates. These low-affinity
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binding interactions are often difficult to characterize with traditional biophysical methods because of the transient nature
of the anesthetic–target complex. The conventional association
or disassociation constant (Ka or Kd) measures the apparent or
time-averaged drug–protein interactions with little binding-site
information. In contrast, saturation transfer difference (STD)
NMR spectroscopy is particularly well suited for quantifying
anesthetic binding to proteins as it is a ligand-based detection
method that can be used to probe low-affinity interactions (Kd in
the micromolar to millimolar range) via selective magnetization
transfer from a macromolecule to a small ligand bound under fast
chemical exchange conditions (Mayer and Meyer, 1999). The rate
of saturation transfer depends on the mobility of the protein and
the ligand, the lifetime of the complex, and ligand-binding geometry (Streiff et al., 2004; Angulo et al., 2010; Venkitakrishnan
et al., 2012). Accordingly, previous studies have shown that the
STD cross-relaxation rate constant (initial growth rate of the
STD signal) is a measure of ligand affinity and can be used to
determine Kd when measured across a range of ligand concentrations (Angulo et al., 2010; Künze et al., 2014, 2016; Zhang et
al., 2017; Chan et al., 2018). In particular, 19F STD NMR experiments are advantageous compared with standard 1H STD NMR
because 19F-NMR background signal is absent in protein, lipids,
and water. Thus, 19F spectra allow for not only differentiation of
signals that are difficult to distinguish in 1H spectra (Danielson
and Falke, 1996; Lepre et al., 2004; Wagstaff et al., 2013) but also
identification of drug-binding site by selective 19F probe placement in the protein. In addition, the gyromagnetic ratio of 19F is
close to that of 1H (γF/γH ∼0.94) (Lepre et al., 2004); the distance
limit of detection for 19F STD NMR measurements is similar to
that of standard 1H STD NMR (r < 10 Å) (Jayalakshmi and Rama
Krishna, 2002, 2004).
The bacterial sodium channel from Bacillus halodurans (NaChBac) is a structural homologue of eukaryotic NaV channels
(Ren et al., 2001) that provides a convenient model to study
the anesthetic interactions with NaV channels because NaChBac is easily produced in large quantities and with high purity.
Several studies have shown that NaChBac, other bacterian NaV
channels, and eukaryotic NaV channels are dose-dependently inhibited by the intravenous general anesthetic propofol (Frenkel
and Urban, 1991; Rehberg and Duch, 1999; Haeseler and Leuwer,
2003; Ouyang et al., 2003; Haeseler et al., 2008; Stoetzer et al.,
2016; Yang et al., in this issue). Although eukaryotic and prokaryotic NaV channels are evolutionarily distinct—with the former
being a single amino acid chain folded into a pseudotetrameric
channel and the latter being a homotetrameric assembly of four
identical subunits—these channels nevertheless share many
similar structural features. Both eukaryotic and prokaryotic NaV
channels consist of four voltage-sensing domains (VSDs), each
composed of S1–S4 helices, and a pore domain (PD) composed
of S5–S6 helices and a P-loop arranged in a tetrameric ring to
form an ion-conducting channel. A helical S4–S5 linker, situated
at the cytoplasmic moiety of the membrane bilayer, connects
the VSD to the PD.
In previous studies, we demonstrated that the volatile general anesthetics isoflurane and sevoflurane dose-dependently
inhibit NaChBac (Barber et al., 2014; Kinde et al., 2016). Using
Wang et al.
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site-directed labeling with small fluorinated probes, we further
quantified the specific binding of isoflurane to various regions in
NaChBac using 19F STD NMR (Kinde et al., 2016). In the current
study, in silico predictions of propofol-binding sites were used
to guide similar site-directed labeling to five different regions of
NaChBac. Unlike isoflurane, propofol does not naturally contain
the fluorine atoms required for 19F STD NMR, so a fluorinated
propofol analogue (4-fluoropropofol) was synthesized. In vivo
measurements of anesthesia were conducted to ensure that the
physiological effects of the analogue were comparable to that
of propofol, and in vitro electrophysiology experiments were
performed to confirm that the mutations required for site-directed labeling in NaChBac did not obstruct channel gating.
Residue-specific binding was quantified by using 19F STD NMR,
and the results indicate that propofol binds to multiple regions
of NaChBac, including a site in the VSD, a pocket near the S4–S5
linker, and within the PD.

Materials and methods

Molecular modeling
No experimental structure is currently available for NaChBac. A
structural model of NaChBac was obtained previously (Barber
et al., 2012) based on the crystal structure of a prokaryotic NaV
channel from Arcobacter butzleri (NavAb) in a putative closedpore conformation with all four VSDs partially activated (PDB
accession no. 3RVY; Payandeh et al., 2011). Four additional structural models of NaChBac in a variety of putative functional states
were obtained by using Modeller 9.17 (Webb and Sali, 2014a,b)
based on experimental crystal structures of prokaryotic NaV
channels from Magnetococcus marinus (NavMs; PDB accession
no. 5HVX; Sula et al., 2017), Rickettsiales sp. HIMB114 (NavRh;
PDB accession no. 4DXW; Zhang et al., 2012), and NavAb (PDB
accession nos. 5VB2 and 5VB8; Lenaeus et al., 2017). For each
crystal structure, 25 independent NaChBac models were generated. The structure with the lowest discrete optimized potential
energy was selected for subsequent docking calculations.
Molecular docking
AutoDock version 4.2.6 (Morris et al., 2009) was used for all
docking calculations. Docking grids with 0.375-Å spacing were
generated to cover the entire transmembrane domain of each
protein structure so that all potential binding sites were considered equally. Both propofol and 4-fluoropropofol were docked
separately to all five NaChBac structural models as well as each
of the original template NaV channel structures by using a Lamarckian genetic algorithm with a population size of 1,000, a
maximum of 27,000 generations, and a maximum of 25 million
energy evaluations. A total of 500 independent docking calculations were clustered by using an RMSD cutoff of 2 Å.
MD simulations
The final frame from previous MD simulations of NaChBac
embedded in a fully hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayer (Barber et al., 2012)
was used as the initial coordinates to simulate flooding NaChBac
with propofol. The flooding simulation was performed by using
Journal of General Physiology
https://doi.org/10.1085/jgp.201811993

1318

NAMD2.10 (Phillips et al., 2005). The simulation system contained a total of ∼122,000 atoms, including a NaChBac tetramer,
434 lipid molecules (POPC), 25,310 water molecules, 236 ions (Cl−
and Na+), and 145 propofol molecules. Thus, the water-to-propofol ratio was 174.6, equivalent to an initial aqueous concentration
of 0.32 M. Initially, all propofol molecules were randomly distributed in the aqueous phase, and two Na+ ions were placed in the
channel selectivity filter, in agreement with a previous computational study of NavAb showing double occupancy of the filter
by Na+ ions (Carnevale et al., 2011). All charged amino acids were
fully ionized at pH 7. The system was equilibrated through three
consecutive stages of 500 ps each, in which position restraints on
different groups were progressively released. The CHARMM36
force field was used for the phospholipids and CHARMM27 for
the protein (Lee et al., 2016). A united-atom representation was
adopted for the acyl chains of the POPC lipid molecules (Hénin et
al., 2008). Propofol parameters were obtained from the literature
(LeBard et al., 2012). Periodic boundary conditions were used,
and the electrostatic potential was evaluated by using the particle
mesh Ewald method. The lengths of all bonds containing hydrogen were constrained with the SHAKE/RATTLE algorithm. The
system was maintained at a temperature of 300°K and pressure
of 1 atm by using the Langevin thermostat and barostat methods
as implemented in NAMD2.10. The reversible reference system
propagation algorithm (rRESPA) multiple time step method
was used, with a high-frequency time step of 2 fs and a low-frequency time step of 4 fs. A trajectory of ∼1 µs was collected for
subsequent analysis.
Site-directed 19F labeling and NMR sample preparation
Single cysteine mutations of NaChBac were prepared by using
the same procedures as detailed previously (Kinde et al., 2016).
In brief, the QuickChange lightning mutagenesis kit (Agilent)
was used to mutate the selected residue to cysteine. The mutated
NaChBac was expressed in lysogeny broth at 18°C, purified by
using a 5-ml Ni column, and eluted with a buffer solution containing 50 mM Tris, 500 mM NaCl, 500 mM imidazole, and 0.1%
n-dodecyl-β-D-maltoside (DDM). Site-directed 19F labeling was
achieved by covalent attachment of 3-bromo-1,1,1-trifluoroacetone (BTFA) to individual cysteine residues. BTFA in 50-fold
excess was added to purified NaChBac mutants and incubated
at 4°C overnight. After the labeling reaction was completed, the
19F-labeled NaChBac in the tetrameric form was purified and
separated from the free BTFA by using size-exclusion chromatography (Superdex 75 10/300 GL column; GE Healthcare). The
protein samples were further concentrated to 100 µM for NMR
measurements. The mutation sites can be grouped into five regions (see Results): (1) the apex of the VSD, including N36C and
V40C in the S1 helix immediately above the hydrophobic constriction site; (2) the hinge region of the S4–S5 linker, including
S129C and L150C; (3) the selectivity filter region, including T189C
at the base of the selectivity filter; (4) the pore region, including
I223C in the middle of the central cavity and F227C at the activation gate; and (5) the extracellular interface, including S208C at
the hinge of the P2 and S6 helices.
To measure cross-relaxation rate constants between propofol
and the fluorinated NaChBac mutants by using 19F STD experiWang et al.
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ments, we used a fluorinated propofol analogue, 4-fluoro-2,6-diisopropylphenol (or 4-fluoropropofol). In a typical NMR sample,
4-fluoropropofol was titrated into the protein samples in a solution of 1–2% DDM, 50 mM Tris at pH 7.7, 100 mM NaCl, 5% D2O for
deuterium locking, and a final concentration of ∼200 µM.
NMR data acquisition and analysis
All NMR experiments were performed on a Bruker Biospin
Avance 600 spectrometer, equipped with a 19F cryoprobe and operated at a Larmor frequency of 564.68 MHz for 19F resonance. To
maintain protein sample stability, the NMR sample temperature
was controlled at 10°C. The STD NMR spectra were acquired by
collecting alternating on-resonance and off-resonance 19F spectra with saturation irradiations at −83.8 and −45.00 ppm, respectively. Saturation was achieved by a train of Gaussian cascade
(Q3.1000)-shaped pulses of 3 ms and an interpulse delay of 3 ms.
Intermolecular 19F STD build-up from the protein resonance to
the ligand resonance was determined by using saturation times
of 0.05, 0.2, 0.5, 1.0, 2.0, and 4.0 s in a randomized order. The intensities and corresponding errors of 4-fluoropropofol 19F spectra were analyzed by using MestRenova v8.1.4 and TopSpin3.5.
The STD data were fit to the following mono-exponential function and analyzed by using Prism 6:
	
STD = ST Dm
  ax(1 − e  −ks  att ) ,

(1)

where
I off  − Io  n

_
   × 100,
	
STD % =  
I  
off

(2)

t is saturation time, and Ion and Ioff are 4-fluoropropofol peak
intensities with on- and off-resonance saturation of the labeled
protein peak, respectively. STDmax is the maximum (plateaued)
STD, and ksat is the observed saturation rate constant. The
cross-relaxation rate constant (σ), which is a direct measure of
ligand-protein interaction strength, can be expressed as
 m
  ax  × ks  at.
	
σ = ST D

(3)

Electrophysiology
The procedures for preparing materials, performing electrophysiology, and data analysis are detailed previously (Yang et
al., 2018b). To generate NaChBac mutants, point mutations
were introduced into the WT plasmid by using the QuickChange
site-directed mutagenesis method (Agilent). HEK-293 cells were
transiently transfected with cDNA by using Lipofectamine 2000
transfection reagent (Invitrogen) and seeded onto 12-mm circular glass coverslips (Fisher Scientific) 24 h before patch-clamp
recording. Standard protocols were followed for growth and
maintenance of cells in culture.
Voltage-dependent activation was assessed with Na+ currents
evoked by 700-ms depolarizing steps (from −100 to +60 mV, ΔV
= 10 mV). The holding potential (Vhold) for NaChBac WT, V40C,
T189C, and F227C was −120 mV; for NaChBac S129C, Vhold was
−160 mV. Prepulse inactivation in NaChBac WT, V40C, T189C,
and F227C was assessed with a two-pulse protocol: (1) a 2-s conditioning pulse (−120 mV to −10 mV, ΔV = 10 mV), followed immediately by (2) a 50-ms test pulse to +10 mV; Vhold was −120 mV. In
Journal of General Physiology
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NaChBac S129C, the conditioning pulse varied from −140 to −20
mV, ΔV = 10 mV; and Vhold was −160 mV. All electrophysiology
data are reported as mean ± SEM from n separate experiments.
Hypnotic activity in albino Xenopus laevis tadpoles
In vivo anesthetizing effects were measured for 4-fluoropropofol and propofol in albino X. laevis tadpoles (stages 45–47) as described previously (Hall et al., 2010; Woll et al., 2015). All animal
care and experimental procedures involving X. laevis tadpoles
were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the University of
Pennsylvania. In brief, tadpoles were incubated for 30 min in
Petri dishes (10 tadpoles per dish) with varying concentrations
of 4-fluoropropofol or propofol dissolved in pond water, containing <0.01% DMSO as vehicle. Hypnosis, or immobility, was
determined by the percentage of tadpoles that did not demonstrate spontaneous movement in a 30-s evaluation period at the
end of the 30-min incubation. After the anesthetic exposures,
the tadpoles were transferred to fresh pond water and observed
overnight for signs of toxicity. The water temperature was maintained at 21–22°C throughout the experiments. Values are represented as the mean ± SEM for three replicates. Data were fit to the
following sigmoidal dose response curve with variable Hill slope:
top − bottom

	
Y = bottom +  ________________
  
  
 ,
(logEC  −X)×HillSlope
1 + 1 0 

50



(4)

where X is the logarithm of the concentrations of propofol or
4-fluoropropofol.
Online supplemental material
Fig. S1 shows changes in NaChBac activation and inactivation gating parameters induced by 4-fluoropropofol. Table S1 shows the
predicted propofol binding sites identified by molecular docking
on template NaV channel crystal structures. Fig. S2 shows the effects of single-cysteine mutations on the function of NaChBac.
Fig. S3 shows the effects of 4-fluoropropofol on NaChBac mutant gating and kinetics. Fig. S4 shows stack plots of 19F STD NMR
spectra between 4-fluoropropofol and NaChBac.

Results

4-Fluoropropofol as a surrogate for propofol
Because propofol does not naturally contain any fluorine atoms,
a fluorinated analogue was needed to measure the strength of
propofol interactions with 19F STD NMR. We synthesized 4-fluoropropofol following a procedure described in the literature
(Yuan et al., 2017) and determined the anesthetizing concentrations of propofol and 4-fluoropropofol in vivo by assessing
immobility in tadpoles. The percentage of immobilized tadpoles
from three separate trials with 10 tadpoles per drug per trial is
plotted in Fig. 1 as a function of drug concentration for propofol or 4-fluoropropofol. The EC50 values, determined from the
nonlinear fitting to the dose–response curves (Eq. 2), are given
as mean (95% confidence interval): propofol, 0.89 (0.82–0.96)
µM and 4-fluoropropofol, 0.84 (0.73–0.97) µM. Hill slopes are
3.21 ± 0.36 and 2.73 ± 0.49 for propofol and 4-fluoropropofol, respectively. The two-tailed Student’s t test shows no significant
Wang et al.
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Figure 1. In vivo anesthetizing concentrations of propofol and 4-fluoropropofol in albino X. laevis tadpoles are identical. The percentage of
immobilized tadpoles is plotted as a function of propofol and 4-fluoropropofol
concentrations. The solid lines are best fit to the data by using Eq. 4. Error bars
show the SEMs from three independent measurements with 10 tadpoles per
measurement at each drug concentration.

difference between the anesthetizing potencies of propofol and
4-fluoropropofol.
In addition to the in vivo effects, we also evaluated the in vitro
functional relevance of using 4-fluoropropofol to probe propofol action through electrophysiological measurements of NaChBac modulation by 4-fluoropropofol. Fig. 2 summarizes paired
electrophysiology measurements in the absence and presence of
4-fluoropropofol. Like propofol, 4 µM 4-fluoropropofol significantly reduced the time constant of inactivation (Fig. 2, A–C) and
induced parallel hyperpolarizing shifts of both the G-V (Fig. 2 D,
left) and prepulse inactivation curves (Fig. 2 E, left). These shifts
corresponded to changes in the midpoint (ΔV1/2) of activation and
inactivation of −14.11 ± 1.87 mV and −10.96 ± 0.80 mV, respectively, closely matching the experimental values for propofol as
detailed in the companion paper (Yang et al., 2018a).
To evaluate lower affinity interactions, we also examined the
functional effects of 4-fluoropropofol at a 10-fold higher (but still
clinically relevant) concentration (Khan et al., 2014). At 40 µM,
4-fluoropropofol induced a dramatic acceleration of the current
decay (Fig. 2, B and C) and inhibited the peak current by 55% as
determined by the average of the paired ratios (Fig. S1 A). This
concentration of 4-fluoropropofol also changed the slope of the
activation curve, giving some indication of hyperpolarization,
but the V1/2 of activation did not change significantly (Fig. 2 D,
right; and Fig. S1 A). It also strongly hyperpolarized the prepulse
inactivation curve, corresponding to a ΔV1/2 of inactivation of
–49.87 ± 5.95 mV, and reduced the associated effective gating
charge (Fig. 2 E, right; and Fig. S1 B). At higher concentrations,
4-fluoropropofol might inhibit NaChBac by pore blockade and
stabilization of the inactivated state, in addition to the gating acceleration effects as seen at lower concentrations (see Discussion).
The combined results of the in vitro and in vivo measurements
validate the physiological relevance of using 4-fluoropropofol as
a fluorinated surrogate of propofol in binding analyses.
Multiple predicted propofol binding sites in NaChBac
As a general anesthetic with relatively low affinity for its protein
targets, propofol likely binds to multiple distinct sites in NaChBac
Journal of General Physiology
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Figure 2. 4-Fluoropropofol modulates voltage-dependent activation and inactivation of NaChBac. (A) Representative paired current families in the
absence (control) and presence of 4 µM 4-fluoropropofol. (B) Paired currents at +20 mV. The 4-µM 4-fluoropropofol trace is shown scaled to its respective
control Ipeak. The 40-µM 4-fluoropropofol trace is shown both as a raw current and scaled to its respective control Ipeak. (C) Time constants of inactivation (τ)
versus voltage of control (n = 20) and 4-fluoropropofol at 4 and 40 µM (n = 8–12). 4-Fluoropropofol reduced τInactivation at both concentrations and all voltages
(P < 0.0001, paired t test). (D and E) Normalized G-V (D) and prepulse (E) inactivation curves of control and 4-fluoropropofol at the indicated concentrations
(n = 5–12). Corresponding midpoints (V1/2) of activation and inactivation are shown below the corresponding curves. Means are indicated in magenta. Data are
reported as mean ± SEM from n independent measurements.

to produce its net inhibitory effects. To broadly examine all potential propofol-binding sites, we used two complementary computational techniques, molecular docking and MD simulations,
as a preliminary screen to guide further experimental quantification. In the molecular docking calculations, both propofol
Wang et al.
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and 4-fluoropropofol were screened on five structural models of
NaChBac in a variety of putative functional states. Four distinct
binding sites were observed with occupancies ≥10% for either
propofol or 4-fluoropropofol (Fig. 3 A and Table 1). Both compounds bound to each of these four sites with similar occupanJournal of General Physiology
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Figure 3. In silico predicted propofol binding sites in NaChBac. (A) Top and side views of a NaChBac structure model with putative propofol binding sites
identified by molecular docking (cyan spheres, occupancy ≥ 10%). (B and C) Zoomed-in views of the lowest energy conformation from docking calculations
of propofol (cyan) bound to NaChBac inside the pore at the selectivity filter (B) and above the activation gate (C). Residues in close proximity to the docked
propofol are shown as sticks labeled with the corresponding color. Note that residues selected for 19F labeling in STD NMR experiments (T189, I223, F227) are
within the binding sites but unlikely to be essential for propofol binding to these regions. (D) Top and side views of NaChBac from the final frame of the 1-µs
flooding MD simulation with putative propofol-binding sites (cyan spheres, occupancy ≥ 90%). (E and F) Zoomed-in views of propofol bound to NaChBac in the
final frame of the 1-µs flooding MD simulation in the apex of the voltage-sensing domain (E) and an intersubunit site at the intracellular interface (F). Residues
in close proximity to the docked propofol are shown as sticks labeled with the corresponding color. Note that residues selected for 19F labeling in STD NMR
experiments (N36, V40, S129, L150) are within the binding sites but unlikely to be essential for propofol binding to these regions.

cies and energies, analogous to the in vitro and in vivo functional
results above, indicating there are no significant differences in
propofol and 4-fluoropropofol binding to NaChBac. In addition,
docking propofol and 4-fluoropropofol to the original (experimental) template crystal structures of NaV channels used to
construct the five NaChBac models did not reveal any additional
binding sites (Table S1).
Docking results from four of the five NaChBac structures
showed the highest propofol/4-fluoropropofol occupancy at the
same binding site within the selectivity filter inside the pore
(Fig. 3 B). One other potential binding site, inside the central
pore cavity directly above the activation gate, was also observed
in two of the five NaChBac structures but with lower occupancy
than the selectivity filter site (Fig. 3 C). The combined docking
results show a high likelihood for propofol binding at these two
sites and consequently both were considered in subsequent 19F
STD NMR experiments. The other two potential binding sites
(the apex of the VSD and an intersubunit site at the extracellular
interface of the PD) were observed in the docking results from
Wang et al.
Residue-specific propofol binding to NaChBac

only one of the five screened NaChBac structures (Table 1); because these docking calculations provide only a rough estimate
of potential propofol binding sites, an additional MD simulation of NaChBac conducted with an excess of propofol was performed to further clarify which sites have the highest potential
for propofol binding.
Within the first 150 ns of the flooding simulation, nearly all
propofol molecules partitioned into the lipid bilayer membrane
and accumulated near the transmembrane surface of NaChBac.
A propofol density map averaged over the course of the following
1-µs simulation revealed two binding sites with >90% occupancy,
i.e., sites where propofol was persistently bound after the initial
equilibration (Fig. 3 D). The first is a site in the apex of the VSD
at the N-terminal end of the S4 helix, matching that observed
previously in molecular docking on one of the screened NaChBac structures (Fig. 3 E). The second is an intersubunit site at the
intracellular interface between the S4–S5 linker helix of one subunit and the S5 and S6 helices of another subunit (Fig. 3 F). With
such a high occupancy throughout the simulation providing
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Table 1. Potential propofol binding sites in NaChBac identified by molecular docking
Binding site

NaChBac template structure (PDB)

Compounda

Selectivity filter

NavAb (3RVY)

PFL

NavAb (5VB2)
NavAb (5VB8)
NavMs (5HVX)
Activation gate

NavAb (5VB8)
NavRh (4DXW)

Voltage sensing domain

NavAb (3RVY)

Intersubunit extracellular interface

NavRh (4DXW)

aPFL,

Occupancy

Lowest energy score

%

kcal/mol

51.2

−6.20

4FPFL

70.2

−6.19

PFL

99.6

−6.76

4FPFL

90.6

−6.53

PFL

98.4

−6.71

4FPFL

81.6

−6.58

PFL

100.0

−6.92

4FPFL

98.2

−6.64

PFL

1.6

−6.56

4FPFL

17.6

−6.44

PFL

19.7

−6.52

4FPFL

33.8

−6.50

PFL

39.6

−6.61

4FPFL

24.0

−6.72

PFL

63.5

−6.49

4FPFL

52.5

−6.53

propofol; 4FPFL, 4-fluoropropofol.

strong in silico evidence of propofol binding, these two potential
sites were also considered in subsequent 19F STD NMR experiments. In total, computational screening implicated four binding
sites for favorable propofol binding: the selectivity filter, the activation gate in the pore, the apex of the VSD, and the S4–S5 linker.
An intrasubunit binding site at the extracellular interface of
the PD, which was confirmed to bind the volatile anesthetic isoflurane (Kinde et al., 2016), was not predicted to bind propofol
by either computational approach. This intrasubunit site (S208)
was also included in the following 19F STD NMR experiments as a
measure of nonspecific propofol binding, i.e., to serve as a negative control for residual 19F magnetization transfer.
Mutational analysis of putative 4-fluoropropofol binding sites
Residue-specific binding analyses with 19F STD NMR require
cysteine residues for selective 19F labeling. Cysteine mutations
are typically well tolerated in membrane proteins; however, any
mutation has the potential to disrupt drug binding. Molecular
details of the putative propofol binding sites predicted by the
computational calculations described above were used to identify
residues within the binding sites that were unlikely to be critical for propofol binding (T189, F227, V40, and S129; Fig. 3). We
then investigated the effects of the introduced cysteines at each
potential binding site on NaChBac channel function and 4-fluoropropofol inhibition. Fig. 4 A compares the voltage dependence
of activation and inactivation for WT and the four NaChBac mutants. The gating parameters are summarized in Table 2. All four
mutants exhibited baseline V1/2 values of activation that were not
statistically different from that of the WT (one-way ANOVA with
Bonferroni post hoc correction), and only S129C demonstrated
Wang et al.
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changes in the effective gating charge of activation. At baseline,
S129C and F227C had prepulse inactivation curves that were
hyperpolarized compared with the WT, whereas that of V40C
was depolarized compared with the WT (Table 2). Cysteine mutations at S129 and F227 reduced the effective gating charge of
inactivation and accelerated the rate of current decay (Fig. S2).
However, the mutations overall were well tolerated, with some
changes seen with mutations at locations critical for gating (e.g.
the S4–S5 linker and activation gate).
The effects of 4 µM 4-fluoropropofol on the voltage dependence of activation and inactivation of each mutant compared
with the WT are depicted in Fig. 4, B–D, and summarized in
Table 3. In all mutants except F227C, 4 µM 4-fluoropropofol
induced hyperpolarizing shifts in the V1/2 values of activation
compared with the respective control without 4-fluoropropofol
(Fig. S3), and the ΔV1/2 of these shifts was not significantly different between the WT and all four mutants (one-way ANOVA
with Bonferroni post hoc correction; Fig. 4 B). In addition, in all
mutants except S129C, the presence of 4 µM 4-fluoropropofol
also produced hyperpolarizing shifts in the V1/2 values of inactivation compared with the respective control (Fig. S3), and
the ΔV1/2 of these shifts was not significantly different between
WT and all mutants except S129C (one-way ANOVA, Bonferroni
post hoc correction). The mutant S129C showed a significantly
smaller ΔV1/2 of inactivation by 4 µM 4-fluoropropofol than the
WT (Fig. 4 C), but this is likely because the S129C mutation already strongly hyperpolarized the prepulse inactivation curve
under basal conditions (Fig. S2). Similar to what we observed
for propofol (Yang et al., 2018a), 4-fluoropropofol accelerated
the rate of current decay (Fig. S3) and in all four mutants, the
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Figure 4. Effects of single-cysteine mutations on NaChBac modulation by 4-fluoropropofol. (A) Paired G-V and prepulse inactivation curves without
(black) and with (light blue) 4 µM 4-fluoropropofol (n = 4–13) for WT and each NaChBac mutant. (B and C) ΔV1/2 values of activation (B) and inactivation (C)
induced by 4 µM 4-fluoropropofol for WT and NaChBac mutants. The ΔV1/2 values of activation were not significantly different between WT and the mutants. Of
the four mutants, only S129C shows significantly different ΔV1/2 of inactivation from the WT (P = 0.0384, one-way ANOVA with Bonferroni post hoc correction).
(D) Fold-change in time constants (τ) of inactivation (τ4-fluoropropofol/τcontrol) at +20 mV induced by 4 µM 4-fluoropropofol. Time constants were derived from
the decaying phase of the Na+ currents, which were well described by the single exponential function. For all mutants, the fold-change in τInactivation caused
by 4 µM 4-fluoropropofol was not significantly different from that of WT (one-way ANOVA with Bonferroni post hoc correction). Data are reported as mean ±
SEM from n independent measurements.
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Table 2. Baseline gating parameters of NaChBac single-cysteine mutants
NaChBac mutant Activation

Inactivation

V1/2

Z

V1/2

Z

mV

e0

mV

e0

WT

−33.93 ± 1.26

3.34 ± 0.19

−54.08 ± 0.53

6.73 ± 0.28

V40C

−28.15 ± 1.62

3.29 ± 0.38

−47.34 ± 1.96***

6.19 ± 0.32

S129C

−41.68 ± 2.64

1.66 ± 0.17*

−77.84 ± 0.65***

3.66 ± 0.33*

T189C

−40.48 ± 1.09

4.23 ± 0.82

−58.04 ± 1.22

7.01 ± 0.33

F227C

−32.56 ± 4.36

2.18 ± 0.21

−60.84 ± 1.73**

5.07 ± 0.57*

Values are given as mean ± SEM (n = 4–12). Gating parameters of NaChBac WT versus each mutant, evaluated by one-way ANOVA with Bonferroni post
hoc correction: *, P < 0.05; **, P < 0.01; ***, P < 0.0001.

fold-change in the time constants of inactivation induced by
4 µM 4-fluoropropofol at +20 mV was not significantly different
from that in the WT (Fig. 4 D). These results provide additional
evidence that the selected cysteine mutations did not hamper
voltage-dependent gating or the functional responses to 4-fluoropropofol, which were generally similar to those for propofol
(Yang et al., 2018a).
Residue-specific interactions quantified by 19F STD
NMR measurements
For each of the four potential propofol binding sites identified by
computational screening (T189, F227, V40, and S129) as well as
the negative control binding site at the extracellular interface of
the PD (S208), single-cysteine NaChBac mutants were prepared
and covalently linked to a BTFA probe to produce residue-specific
19F protein resonance. Additional NaChBac mutants were similarly prepared for three of the putative binding sites for further
confirmation of propofol interactions at the specific sites (I223C,
N36C, and L150C). Mutations to other residues in the predicted
binding site at the selectivity filter were likely to disrupt propofol binding and/or native channel function, so only T189C was
considered at that site. The distance limit of detection for 19F STD
NMR is <10 Å (Jayalakshmi and Rama Krishna, 2002, 2004); the
five regions of NaChBac examined by NMR are separated from

each other by at least 15 Å. Hence, the observed STD signal is produced by 4-fluoropropofol binding close to the 19F-labeled residue and does not include any long-range effects from binding to
another region of NaChBac. The 19F-labeling efficiency for most
mutants was 20–50%, except for N36C and F227C, which had
∼10% 19F labeling efficiency. Because 19F-NMR background signal
is nonexistent in proteins, the relatively low labeling efficiency is
sufficient for STD measurements. In addition, we confirmed that
unlabeled NaChBac produced STD signals for 4-fluoropropofol
that were indistinguishable from noise, i.e., the on- and off-resonance spectra had equal intensities (equal Ion and Ioff in Eq. 2) at
the 4-fluoropropofol peak position, leading to complete cancellation of STD signals. This suggests that (a) unlabeled NaChBac
(NMR invisible) does not interfere with the STD results, and (b)
any imperfections in NMR hardware were below the detection
limit. Note that the functional analysis of cysteine mutations described above was performed for unlabeled NaChBac mutants.
Although labeling with BTFA probe might influence the function
of the NaChBac mutants, this effect would be exceedingly difficult to observe: labeling efficiency in live cells is expected to be
even lower than that achieved for NMR samples. Unlike 19F-NMR
experiments in which only the labeled proteins contribute to the
STD signals, the majority of the response in electrophysiology
experiments would be mostly from unlabeled protein because

Table 3. Changes in NaChBac gating parameters induced by 4 µM 4-fluoropropofol
NaChBac mutant Activation

Inactivation

ΔV1/2

ΔZ

ΔV1/2

mV

e0

mV

ΔZ

e0

WT

−14.11 ±

1.87§§§

0.24 ± 0.32

−10.96 ±

V40C

−14.33 ± 1.20§§§

0.29 ± 0.35

−10.56 ± 1.51§§

−0.28 ± 0.32

−0.17 ± 0.08

−3.73 ± 3.49*

0.20 ± 0.81

0.14§

2.02§

S129C

−6.76 ±

2.37§
1.92§§

T189C

−15.77 ±

F227C

−6.58 ± 3.11

0.80 ±

−0.26 ± 0.18

−8.61 ±

0.80§§§

−17.30 ± 1.29§§§

−0.78 ± 0.21

−0.78 ± 0.26
−4.80 ± 0.58§§,***

Values are given as mean ± SEM (n = 4–13). Control versus 4-fluoropropofol for each mutant, evaluated by paired t test: §, P < 0.05; §§, P < 0.01; §§§, P <
0.001. Change induced by 4-fluoropropofol in NaChBac WT versus in each mutant, evaluated by one-way ANOVA with Bonferroni post hoc correction: *, P
< 0.05; ***, P < 1E-4.
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of low labeling efficiency, essentially nullifying any attempts to
chemically label live cells for functional measurements.
Fig. 5 A depicts representative 19F-NMR spectra showing
well-separated protein and 4-fluoropropofol peaks around −83.8
ppm and −121.7 ppm, respectively. Fig. 5 B is a stack plot of STD
spectra showing an example of strong intermolecular saturation
transfers between 4-fluoropropofol and a BTFA probe placed at
S129C in the S4–S5 linker. Additional 19F-NMR spectra for the
other tested NaChBac mutants are shown in the online supplemental materials (Fig. S4). In contrast to S129C, saturation of the
BTFA resonance linked to S208C produces very weak saturation
transfer to 4-fluoropropofol (Fig. 5 C). Fig. 6 summarizes the STD
accumulations as a function of saturation time for various mutants grouped by binding site. The solid lines are best fit to the
data by using Eq. 1. The cross-relaxation rate constants from the
fitting are summarized in Table 4. As expected, 4-fluoropropofol
does not bind measurably to the intrasubunit site at the extracellular interfacial region (Fig. 6 A): although the maximum STD
accumulation from S208C to 4-fluoropropofol is nonzero (3%),
the curve–fit saturation time constant (ksat) is not different from
zero based on the Student’s t test at the 95% significance level. In
contrast, 4-fluoropropofol shows significant resonance transfer
to residues in all four predicted binding sites (Fig. 6, B–D). The
largest cross relaxation occurs between 4-fluoropropofol and
F227C in the activation gate at the cytoplasmic entrance to the
pore region. The next strongest 4-fluoropropofol cross relaxation is observed in the pocket at apex of the VSD, right above
the hydrophobic constriction site at the crossing of the S4 and S1
helices (N36C, V40C). Another binding site bordered by S129C
at the beginning of the S4–S5 linker and L150C in the S5 helix of
the adjacent subunit also showed strong STD build-up to 4-fluoropropofol. Finally, the end of the selectivity filter (T189C) and
the central cavity of the pore (I223C) also show sizable saturation
transfer from the protein resonance to the 4-fluoropropofol resonance, suggesting that a significant amount of 4-fluoropropofol
is likely trapped inside the pore.

Discussion

In this study, we combined computational prediction and site-directed intermolecular 19F-NMR STD measurements to identify
specific propofol-binding sites in NaChBac. At least four distinct
sites have been identified by their STD cross-relaxation rates. We
do not exclude the possibility that other propofol-binding sites in
NaChBac may exist that were not examined in this study, including the site at the intersubunit extracellular interface (Table 1).
The same intersubunit site was found in a propofol-flooding MD
simulation on NavMs (Yang et al., 2018a). As mentioned in the
introduction, the rate of saturation transfer depends on several
factors, including dynamics of the protein and ligand, residence
time of the ligand in the binding site, and orientation of the 19F
probes on the protein and ligand (Streiff et al., 2004; Angulo et
al., 2010; Venkitakrishnan et al., 2012). As such, the cross-relaxation rate constant is a direct measure of the net magnetization
transfer and hence the binding affinity between the 19F labels on
NaChBac and 4-fluoropropofol. It should be noted, however, that
the σ values cannot be directly interpreted in terms of apparent
Wang et al.
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Figure 5. 19F-NMR measurements of 4-fluoropropofol binding to NaChBac. (A) Representative 19F-NMR spectra of the BTFA-labeled S129C NaChBac
mutant in the presence of 200 µM 4-fluoropropofol with selective on- (black,
Ion) and off-resonance (red, Ioff) saturation of the BTFA peak. The saturation
time was 2 s. (B) Stack plot of 19F STD NMR spectra showing that 4-fluoropropofol interacts specifically with the BTFA labeled at S129C for intermolecular saturation transfer to be built up at longer saturation time (τ). (C) Stack
plot of 19F STD NMR spectra showing that 4-fluoropropofol has no measurable
interaction with the negative control BTFA-labeled S208C NaChBac.

Kd without additional measurements at other ligand concentrations. It should also be noted that the 4-fluoropropofol concentration used in the NMR experiments (200 µM) is higher than those
used in the electrophysiology measurements (4 and 40 µM) because of the low NMR detection sensitivity. However, the clinical
propofol concentration required to produce loss of consciousness
in humans can be as high as 160 µM in the plasma (Khan et al.,
2014), and the plasma concentration is typically only 1–3% of the
total propofol partitioned in the lipophilic compartment of the
blood and brain tissue (Sall et al., 2012).
Journal of General Physiology
https://doi.org/10.1085/jgp.201811993

1326

Table 4. Summary of 4-fluoropropofol binding at various sites in NaChBac
Region

Residue

STDmax

ksat

σ × 100

%

s–1

s−1

Intrasubunit extracellular interface

S208

3.0 ± 1.0*

0.7 ± 0.5

2.1 ± 1.7

Voltage sensing domain

N36

11.4 ± 0.5***

2.0 ± 0.3**

22.3 ± 3.7**

V40

9.1 ± 0.5***

2.8 ± 0.6**

25.5 ± 5.5**

S4–S5 linker

S129

8.4 ± 0.3***

1.9 ± 0.3**

15.8 ± 2.7**

L150

9.5 ± 0.6***

1.6 ± 0.3**

15.5 ± 3.1**

Selectivity filter

T189

9.0 ± 0.5***

2.2 ± 0.4**

19.7 ± 3.8**

Activation gate

F227

17.4 ± 0.9***

2.5 ± 0.4**

42.6 ± 7.6**

I223

9.7 ± 0.5***

1.4 ± 0.2**

13.3 ± 2.3**

I223a

10.0 ±

I223b

8.0 ± 0.5†

0.4†

1.7 ±

0.2†

1.1 ± 0.2†

17.4 ± 1.5††
8.4 ± 1.2††

Values are given as mean ± SEM. Difference from zero was evaluated individually for each parameter by the Student’s t test: *, P < 0.05; **, P < 0.01; ***, P
< 0.001. Difference between parameters obtained in the absence and presence of etidocaine was evaluated by the Student’s t test: †, P < 0.05; ††, P < 0.01.
aMeasured by using 100 µM 4-fluoropropofol without the local anesthetic etidocaine.
bMeasured by using 100 µM 4-fluoropropofol in competition with 50 µM etidocaine.

The four propofol-binding sites identified in this study can
be grouped into three separate regions. The first is in the PD
within the ion-conducting passage, where propofol is found to
interact with residues at the base of the selectivity filter (T189),
inside the central cavity (I223), and at the activation gate (F227).
The other two regions are in the apex of the VSD (N36, V40) and
between the S4–S5 linker and the S5 or S6 helix from an adjacent subunit (S129, L150). At clinically relevant concentrations,
one or more of these binding sites can potentially be occupied.

Figure 6. Quantitative analysis of 19F NMR STD build-up from individual mutation sites in NaChBac to 4-fluoropropofol. Mutations are grouped
by four regions: (A) the extracellular interface (S208), (B) the S4–S5 linker
region (L150C, S129C), (C) the apex of the voltage sensing domain (N36C,
V40C), and (D) the pore region (F227C, I223, T189C). The solid lines are the
best fit to the data by using the two-parameter equation (Eq. 1), yielding the
cross-relaxation rate constant and the saturating magnetization transfer from
the 19F labels on NaChBac to 4-fluoropropofol. Error bars are uncertainties
calculated from the root-mean-squared noise-to-signal ratios in the on- and
off-resonance 19F NMR spectra.
Wang et al.
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Site-directed 19F-NMR measurements strongly support the notion that multiple sites are involved in the allosteric modulation
of NaChBac by propofol. It is also possible that occupancy of these
sites is state dependent because all identified sites are associated
with regions known to change conformation during activation
and/or inactivation of voltage-gated ion channels. In particular,
the aqueous cleft above the hydrophobic constriction site in the
VSD and the interhelical packing between the S4–S5 linker and
its interfacing S5 and S6 helices from the adjacent subunits are
critical for electromechanical coupling. However, because NMR
measurements were necessarily performed at depolarized (zero)
cross-membrane potential, additional experiments are required
to explore this possibility.
The fluorinated propofol partitioned into the channel pore
and showed intermolecular 19F saturation transfer with T189,
the residue that marks the border between the narrow selectivity filter and the broad central aqueous cavity. An interpretation of this result is that the strong and specific interaction
between 4-fluoropropofol and T189 causes drug-induced conformational changes in the selectivity filter (Pavlov et al.,
2005), leading to an accelerated inactivation. An alternative
interpretation supports the notion that high concentrations of
propofol may partition into the pore to directly influence Na+
conductance. However, electrophysiology data detailed in the
companion paper (Yang et al., 2018a) suggest that propofol at
low concentrations does not block the pore of NaChBac. Therefore, it is possible that the central cavity weakly binds propofol
at all pore-lining residues from T189 down to F227. Supporting
this possibility, our results with 40 µM 4-fluoropropofol (Figs.
2 and S1) showed that the predominant action of propofol at
high concentrations involved pore blockade via weak interactions, as indicated by the truncation of the peak current and
dramatically accelerated current decay, suggesting the possible
involvement of blocking kinetics. The accelerated current decay
confounds the hyperpolarizing shift in the G-V curve otherwise
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observed at low propofol and 4-fluoropropofol concentrations.
At 40 µM, 4-fluoropropofol also induced a dramatic hyperpolarizing shift of the prepulse inactivation curve, which additionally appeared shallower, suggesting a slower recovery from
inactivation because of pore blockade-induced stabilization of
the inactivated state.
The site with the largest cross-relaxation rate constant identified in the current study is located at the activation gate (F227;
Fig. 6). As discussed above, the predominant action of propofol
at high concentrations is to accelerate inactivation. This acceleration can be attributed, at least partially, to propofol binding
near the activation gate at F227, especially considering the electrophysiology evidence that the F227C mutation by itself accelerates the rate of current decay and moves the V1/2 of inactivation
significantly in the hyperpolarization direction relative to that
of the WT NaChBac (Table 2 and Fig. S2). Although the F227C
mutation alone did induce a significant shift in the ΔZinactivation
by 4-fluoropropofol compared with WT NaChBac (Table 3), the
strong cross relaxation between fluorine probes at F227 and
4-fluoropropofol suggests that, at the concentration used in
NMR studies, 4-fluoropropofol accumulates inside the pore of
NaChBac. It is conceivable that occupying the site near F227 by
amphipathic drugs like propofol may sensitively promote channel inactivation.
A similar mechanism of action has been proposed for local
anesthetics that block the NaV channel pore and stabilize the
inactivated state (Goldschen-Ohm and Chanda, 2014): mutagenesis experiments have implicated NaV1.2 residues F1764
and Y1771 (equivalent to NaChBac residues T220 and F227,
respectively [Boiteux et al., 2014]) in local anesthetic binding
(Ragsdale et al., 1994). To further investigate whether local anesthetics and propofol have an intersecting site of action in the
pore of NaChBac, we measured the STD signal from I223C to
4-fluoropropofol in the absence and presence of 50 µM etidocaine (Fig. 7). In general, STD NMR experiments are intrinsically insensitive to silent competition partners because the STD
signal is the result of an accumulation of magnetization saturation transfer from the protein to the ligand in fast exchange
over a relatively long acquisition period. However, at a lower
concentration of 4-fluoropropofol (100 µM), the relatively
tight binding of etidocaine (Kd ∼1 µM for the inactivated state
of NaV1.2 [Ragsdale et al., 1994]) allowed us to observe a significant decrease in the cross-relaxation rate of 4-fluoropropofol
binding in the pore of NaChBac (Table 4). Thus, although the
mechanisms may differ, local anesthetics and propofol seem
to share an overlapping site of action. Additional 19F STD NMR
experiments with a fluorinated local anesthetic analogue or
electrophysiological competition experiments could be used to
further support this prediction.
Binding to the apex of the VSD has not been reported before
for any general anesthetic but is supported here by direct experimental measures of intermolecular 19F saturation transfer.
Anesthetic binding at this site likely modulates gating charge
movement. A previous study suggested that the sliding of gating charges across a hydrophobic “girdle” depends on favorable electrostatic interactions of the gating charges against the
complementary surfaces that consist of an extracellular negWang et al.
Residue-specific propofol binding to NaChBac

Figure 7. Local anesthetic inhibition of 4-fluoropropofol 19F NMR STD
signal in the pore of NaChBac. (A and B) Stack plots of 19F STD NMR spectra
for 100 µM 4-fluoropropofol interacting with the BTFA labeled at I223C in the
absence (A) and presence (B) of 50 µM etidocaine, a local anesthetic. (C) 19F
NMR STD accumulation in the absence (black) and presence (red) of 50 µM
etidocaine. The solid lines are the best fit to the data by using the two-parameter equation (Eq. 1), yielding the cross-relaxation rate constant and the
saturating magnetization transfer from the 19F labels on I223C in NaChBac to
4-fluoropropofol. Error bars are uncertainties calculated from the root-meansquare noise-to-signal ratios in the on- and off-resonance 19F NMR spectra.

ative-charge cluster and intracellular negative-charge cluster
(Payandeh et al., 2011). The major energy barrier comes from
moving the gating charges in the S4 helix to pass a focused
electric field at the hydrophobic constriction site. It is conceivable that amphipathic propofol or 4-fluoropropofol molecules
located between the hydrophobic girdle and the hydrophilic
water molecules in the aqueous cleft facilitate the sliding
movement of S4, favoring a transition to the open state. This
is consistent with the parallel leftward shift of the G-V curve
observed in this study with 4-fluoropropofol and in our other
studies with propofol (Yang et al., 2018a). However, it is importJournal of General Physiology
https://doi.org/10.1085/jgp.201811993

1328

ant to note that as the NMR measurements were performed at
depolarized (zero) cross-membrane potential, it is also possible
that the 4-fluoropropofol binding at the apex of VSD is state-dependent and favors activated states (open and inactivated) over
the resting states.
Like the volatile anesthetic isoflurane, 4-fluoropropofol interacts specifically with the 19F labels placed at S129C and L150C,
which in our structure model of NaChBac form a well-defined
intersubunit pocket at the intracellular interface. However, the
contributions of propofol binding at this site to channel function
are complicated by the fact that the S129C mutation alone induced
hyperpolarizing shifts in the voltage-dependence of activation
and inactivation and accelerated the rate of channel inactivation
(Table 2 and Fig. S2). Although our 19F STD measurements provide direct experimental evidence showing the involvement of
the S4–S5 linker in propofol binding, how the binding at this site
facilitates channel activation or accelerates slow inactivation, or
both, requires further investigations. A possible scenario, based
on the novel role of S4–S5 linker in the inactivation of eukaryotic NaV subchannels, is proposed in the companion paper (Yang
et al., 2018a).
Conclusion
Direct experimental evidence from this study supports the notion that the intravenous general anesthetic propofol binds to
multiple sites in the prokaryotic NaV channel NaChBac for allosteric modulation of gating. Propofol produces a net effect
of inhibition to channel function by facilitating the activation
process and potently promoting the slow inactivation process,
shifting the channel population from the resting to the inactivated states. Based on the locations of the propofol binding sites
identified in this study, we hypothesize that propofol binding
in the apex of VSD above the hydrophobic constriction site facilitates channel activation, whereas the binding in the channel
pore, particularly at the activation gate near F227, accelerates
channel inactivation. Propofol binding near the S4–S5 linker site
might play a dual role by promoting opening and entry into an
inactivated state. Additional experiments, however, are required
to confirm these hypotheses.
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